Treatment of Renal Anaemia - Prof. Dr. Iain Macdougall (London, United Kingdom)

Prof. Iain Macdougall (London, UK) presents current treatment standards for renal anaemia.
Iain Macdougall is Professor of Clinical Nephrology at King’s College London and R&D Lead for the Renal Department at King's, as well as the South London Renal Comprehensive Local Research Network lead for the National Institute for Health Research network. He has initiated and conducted seminal multicentre clinical trials on anaemia, particularly renal anemia, including the PIVOTEL and FIND-CKD trials.
His 2024 paper "Anaemia in CKD - treatment standard " has been picked by MARKUS @ HOMe editors as “NDT's Paper of the Month” as part of our cooperation with NDT - Nephrology, Dialysis, Transplantation, the official journal of the European Renal Association.
The interview was recorded on February 20th, 2024.
Moderators: Prof. Dr. Andreas Kronbichler (Innsbruck, Austria) and Prof. Dr. Gunnar Heine (Frankfurt, Germany).
Articles discussed:
Anaemia in CKD - treatment standard.
Macdougall IC
Nephrol Dial Transplant 2023
doi: 10.1093/ndt/gfad250
FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia.
Macdougall IC, Bock AH, Carrera F, Eckardt KU, Gaillard C, Van Wyck D, Roubert B, Nolen JG, Roger SD; FIND-CKD Study Investigators
Nephrol Dial Transplant 2014
doi: 10.1093/ndt/gfu201
Mechanisms of enhanced renal and hepatic erythropoietin synthesis by sodium-glucose cotransporter 2 inhibitors.
Packer M
Eur Heart J 2023
doi: 10.1093/eurheartj/ehad235
Iron Repletion for Patients with Heart Failure and Kidney Dysfunction.
Coyne DW
Clin J Am Soc Nephrol 2023
doi: 10.2215/CJN.0000000000000264
How do SGLT2 inhibitors protect the kidney? A mediation analysis of the EMPA-REG OUTCOME trial.
Wanner C et al.
Nephrol Dial Transplant 2024
doi: 10.1093/ndt/gfae032
Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials.
Wolf M et al. JAMA 2020
doi: 10.1001/jama.2019.22450
Ferric Carboxymaltose in Iron-Deficient Patients with Hospitalized Heart Failure and Reduced Kidney Function.
Macdougall IC, Ponikowski P, Stack AG, Wheeler DC, Anker SD, Butler J, Filippatos G, Göhring UM, Kirwan BA, Kumpeson V, Metra M, Rosano G, Ruschitzka F, van der Meer P, Wächter S, Jankowska EA
Clin J Am Soc Nephrol 2023
doi: 10.2215/CJN.0000000000000223
Intravenous Iron Dosing and Infection Risk in Patients on Hemodialysis: A Prespecified Secondary Analysis of the PIVOTAL Trial.
Macdougall IC, Bhandari S, White C, Anker SD, Farrington K, Kalra PA, Mark PB, McMurray JJV, Reid C, Robertson M, Tomson CRV, Wheeler DC, Winearls CG, Ford I; PIVOTAL Investigators and Committees
J Am Soc Nephrol 2020
doi: 10.1681/ASN.2019090972
Safety of intravenous ferric carboxymaltose versus oral iron in patients with nondialysis-dependent CKD: an analysis of the 1-year FIND-CKD trial.
Roger SD, Gaillard CA, Bock AH, Carrera F, Eckardt KU, Van Wyck DB, Cronin M, Meier Y, Larroque S, Macdougall IC; FIND-CKD Study Investigators
Nephrol Dial Transplant 2017
doi: 10.1093/ndt/gfw264
Defining iron deficiency in patients with heart failure.
Cleland JGF
Nat Rev Cardiol 2024
doi: 10.1038/s41569-023-00951-6
Iron Deficiency in CKD Without Concomitant Anemia.
Wish JB, Anker SD, Butler J, Cases A, Stack AG, Macdougall IC
Kidney Int Rep 2021
A randomized trial of intravenous and oral iron in chronic kidney disease.
Agarwal R, Kusek JW, Pappas MK
Kidney Int 2015
doi: 10.1038/ki.2015.163
From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction?
Ridker PM.
Cardiovasc Res. 2021
doi: 10.1093/cvr/cvab231.
Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease.
Vaziri ND, Zhou XJ
Nephrol Dial Transplant 2009
doi: 10.1093/ndt/gfn601
Intravenous Iron in Patients Undergoing Maintenance Hemodialysis.
Macdougall IC et al.; PIVOTAL Investigators and Committees.
N Engl J Med. 2019
doi: 10.1056/NEJMoa1810742
Normalization of hemoglobin level in patients with chronic kidney disease and anemia.
Drüeke TB et al.; CREATE Investigators.
N Engl J Med. 2006
doi: 10.1056/NEJMoa062276
The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin.
Besarab A et al.
N Engl J Med 1998
doi: 10.1056/NEJM199808273390903
Correction of anemia with epoetin alfa in chronic kidney disease.
Singh AK et al.; CHOIR Investigators
N Engl J Med. 2006
doi: 10.1056/NEJMoa065485
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.
Pfeffer MA et al.; TREAT Investigators.
N Engl J Med. 2009
doi: 10.1056/NEJMoa0907845

[@stevebush8974]

Excellent deep discussion and challenging the expert with many clinically relevant questions. Thanks for this informative format. Gender-balance of moderators maybe to consider in the future